Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.
In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"
There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.
AML Clinical Trials—May 25, 2022
This update provides the first clear signal that MRD responses following DCP-001 vaccination translate into relevant survival benefits for AML patients.
AML Clinical Trials—May 19, 2022
Clinical trial results are in for new drug that provides a treatment option for adult patients that can potentially reduce the number of doctor office visits.
AML Clinical Trials—May 9, 2022
HM43239 has delivered complete remissions in a broad diversity of relapsed or refractory AML patients in an ongoing phase 1/2 clinical trial, including patients with prior failure of other FLT3 inhibitor agents.
AML Clinical Trials—April 18, 2022
Lisa Foster, HealthTree for AML Contributor, provides us an update on two important AML clinical trials looking at immnotherapy options for relapsed/refractory and TP53 positive AML.
AML Clinical Trials—March 21, 2022
A new drug called Uproleselan added to chemotherapy appears to increases the sensitivity of AML blasts to chemotherapy and improve response rates. This combination has the added benefit of potentially reducing the risk of mucositis. Further study results are hoped to be reported by the end of 2022 to determine if Uproleselan can become a major contributor in the treatment of AML.
AML Clinical Trials—March 1, 2022
Annamycin is a new chemotherapy drug with potential in relapsed/refractory AML. It's perks when compared to the currently used chemotherapy include less risk for heart complications and the added benefit of minimal hair loss. This drug is currently in clinical trials and has recently received fast track designation from the FDA.
AML Clinical Trials—February 11, 2022
An experimental drug called epacadostat targets bone forming cells called osteoblasts and has shown to block the progression of leukemia cells in mouse studies. Researchers hypothesize that by blocking leukemia cells and osteoblasts from communicating, we might be able to stop AML.
AML Clinical Trials—January 20, 2022
At the 2021 ASH conference, Dr. Sallman from Moffitt Cancer Center in Florida presents his abstract on the long-term follow-up of Eprenetapopt (APR-246) for p53 mutant MDS and AML patients with ≤ 30% blasts. He hypothesizes that with this new therapy, patients may be able to get treatment pre and post-transplant which could finally lead to improved outcomes and potentially a cure for this difficult-to-treat subset of patients.
AML Clinical Trials—January 19, 2022
Dr. Mannis describes the oral abstact that he presented at the ASH 2021 annual meeting revealing that a new oral decitabine medication combined with another oral medication called venetoclax appears safe, well tolerated and just as effective as IV decitabine. It is Dr. Mannis's hope that this drug combination will become FDA approved in the near future and become the new standard of care for treating older adults with acute myeloid leukemia.
AML Clinical Trials—January 13, 2022
Dr. Chen reports on his research at ASH which found that preliminary results indicate venetoclax plus decitabine is an effective, lower-intensity regimen that is well tolerated for young adults with newly diagnosed adverse-risk AML, producing high rates of complete response, low rates of infections, and low rates of early death.